Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
News Archive Navigation
News Archive Navigation Language
February 2015
-
Why research into rare diseases matters
Hundreds of millions of people worldwide await treatments for rare diseases.
-
Chemical genetics: The sleuthing behind modern drug discovery
Researchers at Novartis are combining modern techniques with an old approach to drug discovery and getting surprising results.
-
Researchers aim to beat trick play by tumors with drug combo
January 2015
December 2014
-
Talking to: Juergen Brokatzky-Geiger, Global Head of Corporate Responsibility at Novartis
In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.
-
A fresh look at fighting glaucoma
Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.
October 2014
-
Treating cataracts, a leading cause of preventable blindness worldwide
Cataracts are a serious but common eye condition affecting more than 20 million worldwide. A patient in Brazil tells her story.
-
Biological battle of the bulge
John Hadcock’s wife Laura gave him an ultimatum: Run the energy out of Sunny, the new puppy, or take her back to the breeder. So Hadcock started running. On his first trip out, he had to stop half a mile in.
-
10 big questions to dissect science papers
Novartis supports promising young scientists who want to improve their chances to attain advanced science degrees.
Pagination
- ‹ Previous page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- › Next page